Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

Jean-Louis Pujol,Johan Vansteenkiste,Luis Paz-Ares Rodríguez,Vanesa Gregorc,Julien Mazieres,Mark Awad,Pasi A Jänne,Michael Chisamore,Anwar M Hossain,Yanyun Chen,J Thaddeus Beck

JTO Clinical and Research Reports（2021）

引用 14|浏览15

暂无评分

摘要

The combination of abemaciclib and pembrolizumab in stage IV NSCLC resulted in greater toxicity compared with that previously reported for each individual treatment. Risk-benefit profile does not warrant further evaluation of the combination in this population.

查看译文

关键词

Abemaciclib,KRAS-mutant,PD-L1 positive non–small cell lung cancer,Pembrolizumab,Squamous

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要